EUCTR2008-005133-30-FI进行中（未招募）不适用
An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 Vaccine
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female subjects will be eligible for participation in this study if they:
- •Are 18 to 59 years of age, inclusive, on the day of screening;
- •Have an understanding of the study and its procedures, agree to its provisions, and give written informed consent prior to study entry;
- •Are generally healthy, as determined by the investigator’s clinical judgment through collection of medical history and performance of a physical examination.
- •Are physically and mentally capable of participating in the study and follow its procedures;
- •Agree to keep a daily record of symptoms for the duration of the study;
- •If female of childbearing potential – have a negative urine pregnancy test result within 24 hours prior to the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be excluded from participation in this study if they:
- •Have a history of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza vaccine;
- •Are at high risk of contracting H5N1 influenza infection (e.g. poultry workers);
- •Currently have or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorders;
- •Have any inherited or acquired immunodeficiency;
- •Have a disease or are currently undergoing a form of treatment or were undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (>800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs;
- •Have a history of severe allergic reactions or anaphylaxis;
- •Have a rash, dermatological condition or tattoos which may interfere with injection site reaction rating;
- •Have received any blood products or immunoglobulins within 90 days prior to study entry;
- •Have donated blood or plasma within 30 days prior to study entry;
- •Have received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study;
- •Have a functional or surgical asplenia;
- •Have a known or suspected problem with alcohol or drug abuse;
- •Were administered an investigational drug within 6 weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product;
- •Are a member of the team conducting this study or are in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study;
- •If female: are pregnant or lactating.
研究者
相似试验
进行中（未招募）
不适用
An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 VaccineEUCTR2008-005133-30-ATBaxter Innovations GmbH230
进行中（未招募）
不适用
A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above - NDEvaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and AboveMedDRA version: 12.0Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-013904-30-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
进行中（未招募）
不适用
An open label phase 1/2 study to assess the immunogenicity and safety of two different dose levels of H1N1 pandemic infuenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years. - A/H1N1 Immunogenicity and safety in infants, children and adolescentsEUCTR2009-013131-38-DEBaxter Innovations GmbH341
进行中（未招募）
不适用
An open label phase 1/2 study to assess the immunogenicity and safety of two different dose levels of H1N1 pandemic infuenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years. - A/H1N1 Immunogenicity and safety in infants, children and adolescentsA/H1N1, Immunogenicity and Safety in Infants, Children and Adolescents, aged 6 months to 17 YearsMedDRA version: 12.0Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-013131-38-ATBaxter Innovations GmbH341
进行中（未招募）
1 期
Study to assess the immunogenicity and safety of GSK's investigational vaccine (GSK3277511A) when given to healthy smokers and ex-smokers after Shingrix vaccinatioHealthy volunteers (chronic obstructive pulmonary disorder [COPD]))MedDRA version: 20.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-002977-24-FRGlaxoSmithKline Biologicals540